MONTGOMERY, TEXAS -- (MARKET WIRE) -- May 07, 2007 -- Metabolic Research, Inc. (OTCBB: MTBR) announced today that it has secured an exclusive license to technologies relating to the use of fungi, plants, and/or animals for the production of anti-inflammatory and analgesic products for the treatment of inflammatory diseases from Dr. David Summers and T.W. Owen, the developers of this patented bio-technology process. The irrevocable assignment covers the globe.
